• Vincenzo Raimondo.
• Rheumatology Unit, Rheumatology Hospital "Madonna dello Scoglio", Cotronei, Italy.
• Medicine (Baltimore). 2022 Nov 25; 101 (47): e31554e31554.

RationaleAdalimumab, an inhibitor of tumor necrosis factor-alpha, is a systemic non-corticosteroid agent approved for the treatment of noninfectious uveitis. Secukinumab, a human monoclonal antibody inhibiting interleukin 17A, is also being investigated as a potential treatment for noninfectious uveitis.Patient ConcernsA 32-year-old Italian woman receiving adalimumab for relapsed anterior uveitis developed axial and peripheral clinical manifestations of spondyloarthritis during treatment.DiagnosisPhysical, laboratory and instrumental examination confirmed axial and peripheral spondyloarthritis associated with uveitis.InterventionWe decided to administer secukinumab 150 mg/month and interrupted the treatment with adalimumab 40 mg/2 weeks.OutcomesThe patient reported an evident remission of symptoms and improvement in clinical conditions.LessonsHere we show the therapeutic efficacy of the switch from adalimumab to secukinumab, with remission of joint symptoms and reduction of inflammation indices, in the absence of new relapses of uveitis. This case suggests that secukinumab is primarily effective and safe on joints pain of an inflammatory nature in patients with anterior uveitis who develop spondyloarthritis as an extra-ocular symptom, while also seeming to be effective in preventing ocular symptoms recurrence.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

15 keywords...

hide…